title: Targeting the vasculature of visceral tumors: novel insights and treatment perspectives.
abstract: BACKGROUND
  Angiogenesis, the formation of new blood vessels from the endothelium of the existing vasculature, describes a crucial process in tumor growth, disease progression, and metastasis. Therefore, the upcoming strategy of inhibiting tumor angiogenesis has generated different treatment modalities, which have been transferred into clinical practice in recent years. Currently, this concept is applied to target the vasculature of different visceral tumors and intensive clinical research has just started.
  
  
  METHODS
  This review summarizes the modifications of systemic treatment of visceral tumors by targeting the vasculature in the past years. Moreover, novel targets and treatment strategies will be discussed to evaluate future directions.
  
  
  RESULTS
  Leading antiangiogenic drugs combined with systemic chemotherapy have been applied with increasing success during the last years. Therefore, the concept of combining vascular targeting agents with established chemotherapeutic regimens has been increasingly adopted into the therapies of different visceral tumors.
  
  
  CONCLUSIONS
  Targeting the vasculature of visceral tumors in combination with established standard tumor therapies includes major clinical potential for future therapy concepts.
authors.affiliation: Department of Surgery, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany.
authors.forename: L V
authors.initials: LV
authors.lastname: Klotz
authors.forename: M E
authors.initials: ME
authors.lastname: Eichhorn
authors.forename: B
authors.initials: B
authors.lastname: Schwarz
authors.forename: H
authors.initials: H
authors.lastname: Seeliger
authors.forename: M K
authors.initials: MK
authors.lastname: Angele
authors.forename: K-W
authors.initials: KW
authors.lastname: Jauch
authors.forename: Christiane J
authors.initials: CJ
authors.lastname: Bruns
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000098:blood supply* / Q000188:drug therapy* / Q000401:mortality; D049109:Cell Proliferation; D059186:Chemoradiotherapy, Adjuvant; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004067:Digestive System Neoplasms / Q000098:blood supply* / Q000188:drug therapy* / Q000401:mortality; D016503:Drug Delivery Systems; D006801:Humans; D007680:Kidney Neoplasms / Q000098:blood supply* / Q000188:drug therapy* / Q000401:mortality; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000503:physiopathology*; D012106:Research; D015996:Survival Rate
chemical_list: D020533:Angiogenesis Inhibitors